Extended Data Fig. 7.
a. Normalized ratio of baseline calcium level measured by Indo-1 followed by calcium flux in response to D-glucuronic acid (GA), glucosamine hydrochloride (G), and neuromedin B (NMB) in GPRC5C-OE (n = 3 experiments) and control (n = 4 experiments) in AML3 cells. b. HA and GPRC5C expression in AML3 and AML5. c. HAS1,2, and 3 expression in AML3 and AML5. n = 3 experiments, except for HAS3 expression in AML3 n = 2 experiments. d. Technical PLA controls of GPRC5C and HA in AML3 and AML5. Plot is representative of one out of three independent experiments. Each independent experiment was performed in two technical replicates. n = 543, 551, 463, 990, 503, and 523 cells for AML3: GPR + HA, GPR only, HA only and AML5: GPR + HA, GPR only, and HA only, respectively. Data presented as mean ± SEM. e. Concentration–response curve of PRESTO-Tango construct of GPRC5C and control vector treated with GA, G, and NMB in HTLA cells. Normalized to luciferase response at the lowest concentration. n = 4 experiments. f. Residue conservation of GPRC5C based on a multiple sequence alignment of 250 homologous proteins extracted from UniRef90. Red: highly conserved; purple: conserved; blue: not conserved; light blue: no conservation information available; yellow background: sequon for N-glycosylation used for mutation analysis within the ECD of the protein; black box: the putative BX7B domain. g. FACS validation of surface protein levels of GPRC5CWT and site-specific mutant (GPRC5C131QQ132) in HTLA cells. h. FACS validation of surface protein levels of GPRC5CWT and site-specific mutant (GPRC5C131AA132) in HTLA cells. i. Concentration-response curve of PRESTO-Tango construct for GPRC5CWT and site-specific mutant (GPRC5C131AA132) at predicted HA interaction site in HTLA cells. n = 6 experiments. j. FACS validation of surface protein levels of GPRC5CWT and site-specific mutants (GPRC5CN53L and GPRC5CN203L) in HTLA cells. k. HA-fluorescein-treated cells quantified for GFP retention in HEK293T cells expressing GPRC5CWT and GPRC5CN53L. FACS plots representing HA retention in each condition. n = 4 experiments, except for GPRC5CWT where n = 7 experiments. l. Concentration-response curve of PRESTO-Tango construct for GPRC5CWT and site-specific mutant (GPRC5CN53L) at predicted HA interaction site in HTLA cells. n = 6 experiments. m. Concentration-response curve of PRESTO-Tango construct for GPRC5CWT treated with tunicamycin in HTLA cells. n = 3 experiments. n. Concentration-response curve of PRESTO-Tango construct for GPRC5CWT treated with PNGase in HTLA cells. n = 3 experiments. All data presented as mean ± SD, except where otherwise stated. Statistical significance was determined using two-tailed t-test. ns, not significant. n indicates the number of replicates. For all experiments, at least two independent experiments were performed. Source numerical data are available in source data.